CLINICAL_TRIALS
trial_result
· 2015-08-19
Clinical Trial Update: Canakinumab in Patients With Active Hyper-IgD Syndrome [Phase 2]
Summary
Phase 2 trial of canakinumab for active Hyper-IgD syndrome due to mevalonate kinase deficiency has completed, with results posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Mevalonate Kinase Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2015-08-19